<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165035</url>
  </required_header>
  <id_info>
    <org_study_id>COSTAR II</org_study_id>
    <nct_id>NCT00165035</nct_id>
  </id_info>
  <brief_title>Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)</brief_title>
  <official_title>Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conor Medsystems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the investigational
      stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison
      to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the
      treatment of single-vessel (one blood vessel) and multi-vessel (two or three blood vessels)
      coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non -inferiority in 8-month Major Adverse Cardiac Events (MACE) and in-segment late lumen
      loss at 9 months between the CoStar™ Paclitaxel-Eluting Coronary Stent System and the TAXUS™
      Express2™ Drug Eluting Coronary Stent System for the treatment of a single de novo lesion per
      vessel in patients with single and multi-vessel coronary disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE defined as a composite of target vessel revascularization, new myocardial infarction (MI), or cardiac death</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In-segment late lumen loss</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device, lesion and procedure success</measure>
    <time_frame>At procedure or hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACE</measure>
    <time_frame>30 days, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary angiography in the angiographic cohort</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1701</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoStar Paclitaxel Drug Eluting Coronary Stent System</intervention_name>
    <description>Drug eluting stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria:

          -  Eligible for percutaneous coronary intervention (PCI)

          -  Documented stable or unstable angina pectoris (Class I, II, III or IV), documented
             ischemia, or documented silent ischemia

          -  Documented LVEF ≥25% within the last 6 weeks.

          -  Eligible for coronary artery bypass graft surgery (CABG)

        Exclusion Criteria:

        General Exclusion Criteria:

          -  Known sensitivity to paclitaxel or polymeric matrices: Translute or PLGA.

          -  Planned treatment with any other PCI device in the target vessel(s).

          -  MI within 72 hours prior to the index procedure

          -  Patient is in cardiogenic shock

          -  Cerebrovascular Accident (CVA) within the past 6 months

          -  Acute or chronic renal dysfunction (creatinine &gt;2.0 mg/dl or &gt;150 µmol/L)

          -  Contraindication to ASA or to clopidogrel

          -  Thrombocytopenia

          -  Active GI bleeding within past three months

          -  Known allergy to stainless steel or cobalt chromium

          -  Any prior true anaphylactic reaction to contrast agents

          -  Patient is currently taking colchicine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean J Kereiakes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital, Cincinnati, Ohio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell W Krucoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Durham, NC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christ Linder</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. J Invasive Cardiol. 2008 Jul;20(7):335-41.</citation>
    <PMID>18599890</PMID>
  </results_reference>
  <results_reference>
    <citation>Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W; COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol. 2008 Apr 22;51(16):1543-52. doi: 10.1016/j.jacc.2008.01.020.</citation>
    <PMID>18420096</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mitch W Krucoff, MD, Principal Investigator</name_title>
    <organization>Duke University Medical Center</organization>
  </responsible_party>
  <keyword>Percutaneous coronary intervention (PCI)</keyword>
  <keyword>Drug eluting stent (DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

